AT
ATXI.US Avenue Therapeutics Inc
- Market cap
- USD 922K
- P/E
- -
- P/B
- 1.77x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATXI.US undervalued?
Graham numberThe Graham number of Avenue Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avenue Therapeutics Inc fundamental analysis
No fundamental analysis for Avenue Therapeutics Inc yet.
Avenue Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Full company profileAvenue Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avenue Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40M | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | 1.40M | - |
| Operating Income | -2.38M | -11.4M | -21.8M | -26.3M | -5.21M | -3.74M | -8.04M | -14.5M | -11.3M | -3.29M | -2.83M |
| EBITDA | -2.38M | -11.7M | 268K | -26.3M | -5.21M | -3.73M | -2.44M | 4.05M | -11.7M | -3.29M | -2.83M |
| Net Income | -3.18M | -12.3M | -21.5M | -25.6M | -5.09M | -3.72M | -3.55M | -10.4M | -11.7M | -2.91M | -2.77M |
| EPS | -5.39 | -28 | -32 | -24 | -4.63 | -3.29 | -122 | -73 | -0.90 | -0.93 | -0.80 |
| Balance Sheet | |||||||||||
| Total Assets | 197K | 22.2M | 4.53M | 8.92M | 3.25M | 3.96M | 6.85M | 1.85M | 2.67M | 2.93M | 1.53M |
| Total Liabilities | 8.45M | 2.79M | 5.16M | 2.12M | 886K | 509K | 3.58M | 1.20M | 816K | 1.10M | 1.61M |
| Shareholders' Equity | -8.25M | 19.4M | -631K | 6.80M | 2.36M | 3.45M | 3.91M | 1.58M | 2.80M | 1.83M | -75.0K |
| Cash & Short-term Investments | 197K | 21.8M | 2.67M | 8.75M | 3.13M | 3.76M | 6.71M | 1.78M | 2.59M | 2.86M | 1.52M |
| Total Debt | 5.87M | - | - | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.63M | -6.80M | -18.2M | -26.3M | -4.61M | -3.75M | -7.60M | -9.45M | -9.03M | -1.83M | -1.78M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.63M | -6.80M | -18.2M | -26.3M | -5.61M | -3.75M | -7.60M | -12.5M | -9.03M | -1.83M | -1.78M |
| Ratios | |||||||||||
| ROE | - | -63.3% | - | -375.8% | -215.7% | -107.9% | -91.0% | -655.9% | -416.6% | -158.8% | - |
| ROA | -1,612.7% | -55.3% | -476.2% | -286.6% | -156.8% | -94.0% | -51.9% | -560.9% | -436.1% | -99.2% | -180.9% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | -207.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Avenue Therapeutics Inc dividends
Avenue Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:75 on Apr 26, 2024.
Who owns Avenue Therapeutics Inc
- Insiders 13.51%
- Institutions 3.97%
- Public & others 82.52%
- Shares outstanding 3.29M
- Free float 2.96M
Top funds holding ATXI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 6.52K | 0.32% | -1.08% | Jan 2025 |
| Fidelity Series Total Market Index | 1.58K | 0.08% | 0.00% | Jan 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 618.00 | 0.03% | 0.00% | Jan 2025 |
| Spartan Extended Market Index Pool E | 71.00 | 0.00% | 0.00% | Jan 2025 |
| NT Ext Equity Mkt Idx Fd - NL | 7.00 | 0.00% | 0.00% | Dec 2024 |
| Northern Trust Extended Eq Market Idx | 6.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 6.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - L | 6.00 | 0.00% | 0.00% | Dec 2024 |
| State St US Extended Mkt Indx NL Cl C | 3.00 | 0.00% | 0.00% | Feb 2025 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 1.00 | 0.00% | 0.00% | Sep 2024 |
| SSgA U.S. Total Market Index Strategy | 1.00 | 0.00% | 0.00% | Jun 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T4 | 1.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T3 | 1.00 | 0.00% | 0.00% | Dec 2024 |
Top institutions holding ATXI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 140K | 6.82% | 0.00% | Dec 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 41.1K | 2.00% | 0.00% | Dec 2024 |
| UBS Group AG | 7.92K | 0.39% | +28.93% | Dec 2024 |
| Tower Research Capital LLC | 3.10K | 0.15% | +77.93% | Dec 2024 |
| Wells Fargo & Co | 500.00 | 0.02% | -10.87% | Dec 2024 |
| Bank of America Corp | 14.00 | 0.00% | +40.00% | Dec 2024 |
| SBI Securities Co Ltd | 9.00 | 0.00% | 0.00% | Dec 2024 |
| Moss Adams Wealth Advisors LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Sabby Management LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Northern Trust Investments N A | 0.00 | 0.00% | -100.00% | Dec 2024 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
Avenue Therapeutics Inc company profile
- Company name
- Avenue Therapeutics Inc
- Ticker
- ATXI.US
- Exchange
- USA Stocks
- Listed since
- Jun 27, 2017
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1
- Fiscal year end
- December
- Address
- 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
- Phone
- 781 652 4500
- Website
- avenuetx.com
About Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Avenue Therapeutics Inc management
3- Dr. Alexandra MacLean M.D.CEO & Director · born 1968
- Mr. David JinInterim CFO, COO & Corporate Secretary · born 1990
- Dr. Lindsay Allan Rosenwald M.D.Executive Director · born 1955